{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:47:09Z","timestamp":1790790429723,"version":"4.1.0"},"reference-count":61,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"unspecified","delay-in-days":135,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2025,10,23]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an inflammatory, immune-mediated neuropathy of the peripheral nerves and nerve roots. CIDP is unlikely to be a discrete disease entity, but rather a spectrum of related conditions, in which cell-mediated and humoral mechanisms act synergistically to cause damage to peripheral nerves. The 2021 guideline of the European Academy of Neurology\/Peripheral Nerve Society on the diagnosis and treatment of CIDP has modified the CIDP spectrum to include typical CIDP and four well-defined CIDP variants. Patients with CIDP usually respond well to immunoglobulin therapy, steroids or plasmapheresis; however, 20\u201330% do not respond well, and approximately 15% remain refractory to all treatment modalities. Rituximab, mycophenolate mofetil and cyclophosphamide are of therapeutic benefit for some of these patients. Patients with some CIDP variants respond less well to immunotherapy, suggesting a difference in the pathogenic mechanisms underlying these variants. Potential novel treatments trialled in CIDP, targeting functionally relevant disease mechanisms, include neonatal Fc receptor blockers and complement inhibitors. These new treatment approaches are needed to optimise disease outcomes in refractory patients, and as an alternative for patients with suboptimal response requiring high doses or experiencing side effects from first-line therapies. Increasing the therapeutic options for patients with CIDP, particularly for refractory patients, highlights the need for more accurate diagnosis of typical CIDP and CIDP variants, objective evidence of treatment response and the need for reliable clinical biomarkers.<\/jats:p>","DOI":"10.1136\/bmjno-2025-001318","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:15:17Z","timestamp":1763100917000},"page":"e001318","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct06290128","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lynette","family":"Kiers","sequence":"first","affiliation":[{"name":"Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"Department of Medicine (RMH), The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8383-1667","authenticated-orcid":false,"given":"Belinda","family":"Cruse","sequence":"additional","affiliation":[{"name":"Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"Department of Medicine (RMH), The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"2025111322151350000_7.2.e001318.1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12455"},{"key":"2025111322151350000_7.2.e001318.2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309697"},{"key":"2025111322151350000_7.2.e001318.3","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01117-3"},{"key":"2025111322151350000_7.2.e001318.4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/TCRM.S360249","article-title":"Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives","volume":"20","author":"van Doorn","year":"2024","journal-title":"Ther Clin Risk Manag"},{"key":"2025111322151350000_7.2.e001318.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117098"},{"key":"2025111322151350000_7.2.e001318.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70329-0"},{"key":"2025111322151350000_7.2.e001318.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30378-2"},{"key":"2025111322151350000_7.2.e001318.8","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"2025111322151350000_7.2.e001318.9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320741"},{"key":"2025111322151350000_7.2.e001318.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318714"},{"key":"2025111322151350000_7.2.e001318.11","doi-asserted-by":"crossref","first-page":"120478","DOI":"10.1016\/j.jns.2022.120478","article-title":"Tips in navigating the diagnostic complexities of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"443","author":"Lewis","year":"2022","journal-title":"J Neurol Sci"},{"key":"2025111322151350000_7.2.e001318.12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320314"},{"key":"2025111322151350000_7.2.e001318.13","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01221-y"},{"key":"2025111322151350000_7.2.e001318.14","doi-asserted-by":"crossref","first-page":"103032","DOI":"10.1016\/j.autrev.2022.103032","article-title":"Potential therapeutic strategies in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"21","author":"Hu","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2025111322151350000_7.2.e001318.15","doi-asserted-by":"crossref","first-page":"578360","DOI":"10.1016\/j.jneuroim.2024.578360","article-title":"Immune dysregulation in chronic inflammatory demyelinating polyneuropathy","volume":"391","author":"Li","year":"2024","journal-title":"J Neuroimmunol"},{"key":"2025111322151350000_7.2.e001318.16","doi-asserted-by":"publisher","DOI":"10.1177\/1756285611405564"},{"key":"2025111322151350000_7.2.e001318.17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.0000000000001833","article-title":"CIDP diagnostic pitfalls and perception of treatment benefit","volume":"85","author":"Allen","year":"2015","journal-title":"Neurology (ECronicon)"},{"key":"2025111322151350000_7.2.e001318.18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/acn3.51754","article-title":"CIDP\/autoimmune nodopathies with nephropathy: a case series study","volume":"10","author":"Tang","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"2025111322151350000_7.2.e001318.19","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/brain\/awx124","article-title":"Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy","volume":"140","author":"Delmont","year":"2017","journal-title":"Brain (Bacau)"},{"key":"2025111322151350000_7.2.e001318.20","doi-asserted-by":"crossref","first-page":"1326874","DOI":"10.3389\/fneur.2024.1326874","article-title":"Insights into refractory chronic inflammatory demyelinating polyneuropathy: a comprehensive real-world study","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Neurol"},{"key":"2025111322151350000_7.2.e001318.21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.194324"},{"key":"2025111322151350000_7.2.e001318.22","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awab422","article-title":"Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy","volume":"145","author":"Cornblath","year":"2022","journal-title":"Brain (Bacau)"},{"key":"2025111322151350000_7.2.e001318.23","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.105"},{"key":"2025111322151350000_7.2.e001318.24","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.653734","article-title":"Treatment Approaches for Atypical CIDP","volume":"12","author":"Menon","year":"2021","journal-title":"Front Neurol"},{"key":"2025111322151350000_7.2.e001318.25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jns.12380","article-title":"Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment","volume":"25","author":"Pegat","year":"2020","journal-title":"J Peripher Nerv Syst"},{"key":"2025111322151350000_7.2.e001318.26","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308452"},{"key":"2025111322151350000_7.2.e001318.27","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/brain\/awh222","article-title":"Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome","volume":"127","author":"Viala","year":"2004","journal-title":"Brain (Bacau)"},{"key":"2025111322151350000_7.2.e001318.28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mus.28436","article-title":"Mycophenolate Facilitates Improvement in Outcome Measures in Treatment Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy","volume":"72","author":"Miah","year":"2025","journal-title":"Muscle Nerve"},{"key":"2025111322151350000_7.2.e001318.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"2025111322151350000_7.2.e001318.30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/ITT.S388151","article-title":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks","volume":"13","author":"Rajabally","year":"2024","journal-title":"Immunotargets Ther"},{"key":"2025111322151350000_7.2.e001318.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8462-7"},{"key":"2025111322151350000_7.2.e001318.32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.188912"},{"key":"2025111322151350000_7.2.e001318.33","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26804"},{"key":"2025111322151350000_7.2.e001318.34","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000149","article-title":"Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins","volume":"2","author":"Querol","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025111322151350000_7.2.e001318.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.05.013"},{"key":"2025111322151350000_7.2.e001318.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11759-2"},{"key":"2025111322151350000_7.2.e001318.37","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/brain\/awae400","article-title":"Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial","volume":"148","author":"Nobile-Orazio","year":"2025","journal-title":"Brain (Bacau)"},{"key":"2025111322151350000_7.2.e001318.38","doi-asserted-by":"crossref","DOI":"10.2196\/17117","article-title":"Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial","volume":"9","author":"Shimizu","year":"2020","journal-title":"JMIR Res Protoc"},{"key":"2025111322151350000_7.2.e001318.39","doi-asserted-by":"crossref","unstructured":"Iijima M , Shimizu S , Fukami Y , et al . Efficacy and safety of rituximab in refractory chronic inflammatory demyelinating polyneuropathy with immunoglobulin G4 autoantibodies: a multicenter. 2024. doi:10.2139\/ssrn.4905375","DOI":"10.2139\/ssrn.4905375"},{"key":"2025111322151350000_7.2.e001318.40","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332844"},{"key":"2025111322151350000_7.2.e001318.41","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/jns.12653","article-title":"Long-term and low-dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy","volume":"29","author":"Zheng","year":"2024","journal-title":"J Peripher Nerv Syst"},{"key":"2025111322151350000_7.2.e001318.42","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1212\/WNL.51.6.1735","article-title":"Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy","volume":"51","author":"Good","year":"1998","journal-title":"Neurology"},{"key":"2025111322151350000_7.2.e001318.43","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/WNL.58.12.1856","article-title":"High-dose cyclophosphamide without stem-cell rescue for refractory CIDP","volume":"58","author":"Brannagan","year":"2002","journal-title":"Neurology"},{"key":"2025111322151350000_7.2.e001318.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1085-9489.2005.10104.x"},{"key":"2025111322151350000_7.2.e001318.45","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.clinthera.2022.06.008","article-title":"Cyclophosphamide for Treatment of Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-analysis","volume":"44","author":"Xiang","year":"2022","journal-title":"Clin Ther"},{"key":"2025111322151350000_7.2.e001318.46","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8599-4"},{"key":"2025111322151350000_7.2.e001318.47","doi-asserted-by":"crossref","first-page":"1756286421999631","DOI":"10.1177\/1756286421999631","article-title":"Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study","volume":"14","author":"Motte","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2025111322151350000_7.2.e001318.48","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306014"},{"key":"2025111322151350000_7.2.e001318.49","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10010-6"},{"key":"2025111322151350000_7.2.e001318.50","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1111\/ene.15857","article-title":"Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta\u2010analysis","volume":"30","author":"Zheng","year":"2023","journal-title":"Euro J of Neurology"},{"key":"2025111322151350000_7.2.e001318.51","doi-asserted-by":"crossref","first-page":"100704","DOI":"10.1016\/j.medj.2025.100704","article-title":"Anti-BCMA CAR-T cell therapy in relapsed\/refractory chronic inflammatory demyelinating polyneuropathy","volume":"6","author":"Dong","year":"2025","journal-title":"Med"},{"key":"2025111322151350000_7.2.e001318.52","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(25)00199-1","article-title":"CD19-targeted CAR T-cell therapy for treatment-refractory autoimmune neuropathies","volume":"24","author":"Motte","year":"2025","journal-title":"Lancet Neurol"},{"key":"2025111322151350000_7.2.e001318.53","doi-asserted-by":"crossref","DOI":"10.1111\/jns.70010","article-title":"Eculizumab as a Disease-Modifying Therapy in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Case Report","volume":"30","author":"Schilke","year":"2025","journal-title":"J Peripher Nerv Syst"},{"key":"2025111322151350000_7.2.e001318.54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/jns.12646","article-title":"Efficacy and safety of eculizumab in Guillain-Barr\u00e9 syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial","volume":"29","author":"Kuwabara","year":"2024","journal-title":"J Peripher Nerv Syst"},{"key":"2025111322151350000_7.2.e001318.55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1305"},{"key":"2025111322151350000_7.2.e001318.56","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000204596","article-title":"Preliminary Efficacy and Safety Data from the Phase 2 Trial of Riliprubart (SAR445088), a Humanized Monoclonal Antibody Targeting Complement C1s, in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (S15.008)","volume":"102","author":"Querol","year":"2024","journal-title":"Neurology"},{"key":"2025111322151350000_7.2.e001318.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102366"},{"key":"2025111322151350000_7.2.e001318.58","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S1474-4422(24)00362-4","article-title":"Targeting auto-antibodies for CIDP: hope and questions","volume":"23","author":"Rajabally","year":"2024","journal-title":"Lancet Neurol"},{"key":"2025111322151350000_7.2.e001318.59","doi-asserted-by":"crossref","first-page":"123355","DOI":"10.1016\/j.jns.2024.123355","article-title":"Unresolved issues with efgartigimod in CIDP, and broader concerns for future trial design","volume":"468","author":"Katz","year":"2025","journal-title":"J Neurol Sci"},{"key":"2025111322151350000_7.2.e001318.60","doi-asserted-by":"crossref","first-page":"123313","DOI":"10.1016\/j.jns.2024.123313","article-title":"Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment","volume":"468","author":"Levine","year":"2025","journal-title":"J Neurol Sci"},{"key":"2025111322151350000_7.2.e001318.61","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-333112"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T06:15:22Z","timestamp":1763100922000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,13]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjno-2025-001318"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001318","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}